Intech Investment Management LLC Buys 57,455 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Intech Investment Management LLC raised its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 593.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,132 shares of the specialty pharmaceutical company's stock after acquiring an additional 57,455 shares during the period. Intech Investment Management LLC owned approximately 0.21% of Collegium Pharmaceutical worth $1,923,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Caprock Group LLC bought a new stake in shares of Collegium Pharmaceutical during the 3rd quarter worth approximately $315,000. Segall Bryant & Hamill LLC raised its position in Collegium Pharmaceutical by 1.7% during the third quarter. Segall Bryant & Hamill LLC now owns 79,636 shares of the specialty pharmaceutical company's stock valued at $3,077,000 after purchasing an additional 1,329 shares in the last quarter. Foundry Partners LLC lifted its stake in Collegium Pharmaceutical by 3.3% during the third quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company's stock worth $610,000 after purchasing an additional 509 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of Collegium Pharmaceutical by 17.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company's stock valued at $29,586,000 after purchasing an additional 116,327 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Collegium Pharmaceutical by 4.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 381,494 shares of the specialty pharmaceutical company's stock valued at $14,741,000 after purchasing an additional 16,655 shares during the last quarter.

Remove Ads

Analyst Upgrades and Downgrades

COLL has been the topic of several research analyst reports. Needham & Company LLC raised Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price objective on the stock in a research note on Friday, January 10th. Piper Sandler decreased their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a report on Tuesday, February 4th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Monday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $43.60.

Collegium Pharmaceutical Trading Down 1.3 %

COLL traded down $0.41 during trading on Tuesday, reaching $30.15. 212,158 shares of the company's stock were exchanged, compared to its average volume of 418,746. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a one year low of $27.28 and a one year high of $42.29. The firm has a fifty day moving average price of $30.63 and a two-hundred day moving average price of $32.59. The stock has a market capitalization of $949.30 million, a PE ratio of 13.00 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. As a group, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 1,949 shares of the company's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $30.00, for a total transaction of $58,470.00. Following the sale, the chief financial officer now owns 177,195 shares of the company's stock, valued at approximately $5,315,850. This represents a 1.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the sale, the executive vice president now owns 154,204 shares of the company's stock, valued at approximately $4,330,048.32. The trade was a 20.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 109,193 shares of company stock worth $3,243,594 over the last ninety days. 3.98% of the stock is owned by insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.